Craig-Hallum lowered the firm’s price target on Avid Bioservices to $16 from $22 and keeps a Buy rating on the shares. Companies selling products and services into the pharma/biotech industry faced stiff headwinds last quarter, and Avid Bioservices was no exception, the analyst tells investors in a research note. Avid is seeing some signs of improvement, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CDMO:
- Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023
- CDMO Earnings this Week: How Will it Perform?
- Alkermes, Armstrong World, National Healthcare, PJT Partners to join S&P 600
- Avid Bioservices partners with CIRM to provide CDMO services for CGT programs
- Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs
